Stock Events

Stock Events

Israel Canada Hotels 

ILA115.30
0
+ILA2.20+1.95% 12:21 Today

Statistics

Day High
115.3
Day Low
114.2
52W High
151.5
52W Low
83.1
Volume
18,160
Avg. Volume
176,092
Mkt Cap
14.2B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-41.27%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
30BRevenue
-12.38BNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.97B
CRISPR Therapeutics is involved in gene editing, a direct competitor in the genomic medicine field.
Editas Medicine
EDIT
Mkt Cap410.06M
Editas Medicine operates in the CRISPR gene editing sector, competing in the same technology space as DNA (T.R.).
Intellia Therapeutics
NTLA
Mkt Cap1.75B
Intellia Therapeutics is another key player in the CRISPR technology space, making it a direct competitor.
Beam Therapeutics
BEAM
Mkt Cap2.81B
Beam Therapeutics uses base editing, a novel form of gene editing, positioning it as a competitor in genetic engineering.
Alnylam Pharmaceuticals
ALNY
Mkt Cap22.1B
Alnylam Pharmaceuticals focuses on RNAi therapeutics, which are related to gene therapy, competing in the broader genetic medicine field.
Sarepta Therapeutics
SRPT
Mkt Cap1.97B
Sarepta Therapeutics specializes in precision genetic medicine, particularly for rare diseases, overlapping with DNA (T.R.)'s market.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.33B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for rare diseases, a similar target market.
Vertex Pharmaceuticals
VRTX
Mkt Cap141.65B
Vertex Pharmaceuticals engages in several areas including CRISPR therapies for genetic diseases, making it a competitor in gene editing.

About

Israel Canada Hotels Ltd, operating through its various subsidiaries, is globally involved in the creation, production, and distribution of patented ultrasound technology. These advanced systems are instrumental in assessing bone strength and density, alongside tracking calcium loss, especially for diagnosing osteoporosis in both adults and children. Beyond its medical device activities, the company also engages in the development of oral pharmaceuticals. Incorporated in 2004 and based in Tel Aviv, Israel, the entity, which was previously known as Dna Group (T.R.) Ltd, is set to formally adopt the name Israel Canada Hotels Ltd in November 2025.
Show More
CEO
Erez Navon
Employees
14
Country
Israel
ISIN
IL0011038523

Listings

TA
IL
ICHO.TA

0 Comments

Share your thoughts

FAQs

What is Israel Canada Hotels stock price today?▼
The current price of ICHO.TA is ILA115.30 ILA — it has increased by +1.95% in the past 24 hours. Watch Israel Canada Hotels stock price performance more closely on the chart.
What is Israel Canada Hotels stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Tel Aviv Exchange exchange Israel Canada Hotels stocks are traded under the ticker ICHO.TA.
What is Israel Canada Hotels market cap?▼
Today Israel Canada Hotels has the market capitalization of 14.2B
What is Israel Canada Hotels revenue for the last year?▼
Israel Canada Hotels revenue for the last year amounts to 30B ILA.
What is Israel Canada Hotels net income for the last year?▼
ICHO.TA net income for the last year is -12.38B ILA.
How many employees does Israel Canada Hotels have?▼
As of November 2, 2026, the company has 14 employees.
In which sector is Israel Canada Hotels located?▼
Israel Canada Hotels operates in the Lifestyle & Brands sector.
When did Israel Canada Hotels complete a stock split?▼
The last stock split for Israel Canada Hotels was on November 10, 2019 with a ratio of 1:6.
Where is Israel Canada Hotels headquartered?▼
Israel Canada Hotels is headquartered in Herzliya, Israel.